Bcl-XL protein is markedly decreased in UVB-irradiated basal cell carcinoma cell lines through proteasome-mediated degradation

Oncology Reports

Volumn 21, Issue 3, 2009, Pages 689-692

  Park, Kun ^a   Lee, Ji Hye ^a  

^a Eulji University   (South Korea)

Author keywords

Basal cell carcinoma; Bcl XL protein; Proteasome

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CURCUMIN; DNA; MESSENGER RNA; PROTEASOME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; PROTEIN BAD; PROTEIN BCL X;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION RESPONSE; ULTRAVIOLET B RADIATION; BIOSYNTHESIS; DNA FRAGMENTATION; GENE EXPRESSION; METABOLISM; RADIATION EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; ULTRAVIOLET RADIATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA, BASAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DNA FRAGMENTATION; GENE EXPRESSION; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ULTRAVIOLET RAYS;

EID: 64849103460     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000272     Document Type: Article

References (17)

1. Rigel DS: Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol (Suppl 2): S129-S132, 2008.
2. English DR, Armstrong BK, Kricker A and Fleming C: Sunlight and cancer. Cancer Causes Control 8: 271-283, 1997.
3. Meehan SA, Egbert BM and Rouse RV: Basal cell carcinoma with tumor epithelial and stromal giant cells: a variant of pleomorphic basal cell carcinoma. Am J Dermatopathol 21: 473-478, 1999.
4. Cutlan RT and Maluf HM: Immunohistochemical characterization of pleomorphic giant cells in basal cell carcinoma. J Cutan Pathol 26: 353-356, 1999.
5. Yen HT, Chiang LC, Wen KH, Tsai CC, Yu CL and Yu HS: The expression of cytokines by an established basal cell carcinoma cell line (BCC-1/KMC) compared with cultured normal keratinocytes. Arch Dermatol Res 288: 157-161, 1996.
6. Medema JP, Scaffidi C, Krammer PH and Peter ME: Bcl-xL acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex. J Biol Chem 273: 3388-3393, 1998.
7. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3: 614-620, 1997.
8. Kroemer G, Zamzami N and Susin SA: Mitochondrial control of apoptosis. Immunol Today 18: 44-51, 1997.
9. Lanave C, Santamaria M and Saccone C: Comparative genomics: the evolutionary history of the Bcl-2 family. Gene 333: 71-79, 2004.
10. Huang Z: Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19: 6627-6631, 2000.
11. Kreuter M, Langer C, Kerkhoff C, Reddanna P, Kania AL, Maddika S, Chlichlia K, Bui TN and Los M: Stroke, myocardial infarction, acute and chronic inflammatory diseases: caspases and other apoptotic molecules as targets for drug development. Arch Immunol Ther Exp 52: 141-155, 2004.
12. Ghavami S, Hashemi M, Kadkhoda K, Alavian SM, Bay GH and Los M: Apoptosis in liver diseases-detection and therapeutic applications. Med Sci Monit 11: RA337-RA345, 2005.
13. Hauff K, Zamzow C, Law WJ, de Melo J, Kennedy K and Los M: Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system. Arch Immunol Ther Exp 53: 308-320, 2005.
14. Mendoza FJ, Espino PS, Cann KL, Bristow N, McCrea K and Los M: Anti-tumor chemotherapy utilizing peptide-based approachesapoptotic pathways, kinases, and proteasome as targets. Arch Immunol Ther Exp. 53: 47-60, 2005.
15. Johnson GE, Ivanov VN and Hei TK: Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis 13: 790-802, 2008.
16. Cao X, Rodarte C, Zhang L, Morgan CD, Littlejohn J and Smythe WR: Bcl2/ bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol Ther 6: 246-252, 2007.
17. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U and Gleave ME: Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int 97: 1300-13008, 2006.